Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo
about
SLC transporters as therapeutic targets: emerging opportunitiesIcotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2.Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug ResistanceMBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenograftsThe small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study.Isolation and characterization of side population cells from the human ovarian cancer cell line SK-OV-3A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo.ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics.Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer.ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.Esters of the marine-derived triterpene sipholenol A reverse P-GP-mediated drug resistance.Pharmacokinetic interactions in mice between irinotecan and MBL-II-141, an ABCG2 inhibitor.ABCG2/BCRP: Specific and Nonspecific Modulators.Gibberellin derivative GA-13315 sensitizes multidrug-resistant cancer cells by antagonizing ABCB1 while agonizes ABCC1.Mycoplasma-associated multidrug resistance of hepatocarcinoma cells requires the interaction of P37 and Annexin A2.Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.
P2860
Q27014726-D295F930-D2C1-4270-8422-A9A9DDF7757AQ34101040-E204B96F-7134-4350-8E5F-AF751C780003Q34774854-A6EF4459-D3AE-4BF2-ABBD-ACFBB75F1AF2Q35068041-585AF44F-C883-40BF-A9C0-56ED692DC3DAQ35238509-B51FF39A-C612-477C-870B-72E291D5ED9AQ36334147-2A3FB861-93AA-4604-B8DB-5F6CFB7039D5Q36629578-1437BFA6-D75F-4CEF-8732-F2CAC52D266FQ37563366-832900F8-481C-4806-ABC3-D7BAA164B97CQ38246305-60E25B2E-25BB-4BBC-91B3-9179B2CCEB6AQ38707907-51329D09-562D-45B6-A984-FEE8080C3728Q38848383-703B1725-1390-4E13-B816-576C6EAED722Q38887070-EFA0C269-F0A2-489C-B4D7-6E01A18745E9Q38957795-49B7C054-673D-4B59-A7CF-1019F42DFD16Q39049159-4DD53C03-6CEE-4DE8-A811-44D8B6C1DD4FQ39782004-C5B53839-5C90-40A0-B383-E14E55ED13F8Q42370180-FEC55AC1-968B-4B77-8BD1-758A2DE36F31Q49888021-B64F69ED-5566-4E3A-A0A3-B53BF64E89C4
P2860
Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Telatinib reverses chemotherap ...... ansporter in vitro and in vivo
@en
type
label
Telatinib reverses chemotherap ...... ansporter in vitro and in vivo
@en
prefLabel
Telatinib reverses chemotherap ...... ansporter in vitro and in vivo
@en
P2093
P2860
P1476
Telatinib reverses chemotherap ...... ansporter in vitro and in vivo
@en
P2093
Atish Patel
Dong-Hua Yang
Kamlesh Sodani
Rishil J Kathawala
Satyakam Singh
Tanaji T Talele
Zhe-Sheng Chen
P2860
P356
10.1016/J.BCP.2014.02.012
P407
P577
2014-02-22T00:00:00Z